Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 51 clinical trials
featured
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

advanced lung cancer
systemic therapy
adjuvant chemotherapy
lung cancer
cancer
  • 358 views
  • 08 Dec, 2020
  • 4 locations
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

This study will compare the effectiveness of osimertinib alone with the combination of osimertinib and chemotherapy (carboplatin and pemetrexed) in people with metastatic lung cancer that has a

gilbert's syndrome
pemetrexed
neutrophil count
carboplatin
lung metastases
  • 0 views
  • 17 Jan, 2021
  • 11 locations
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR

epidermal growth factor receptor
measurable disease
cancer treatment
EGFR
growth factor
  • 27 views
  • 18 Jan, 2021
  • 282 locations
Osimertinib In EGFR Mutant Lung Cancer

is: Osimertinib (Tagrisso)

secondary malignant neoplasm of liver
ct scan
measurable disease
neutrophil count
EGFR
  • 3 views
  • 25 Jan, 2021
Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLC

Investigating potential of controlling brain metastases in patients with EGFR positive NSCLC.

secondary malignant neoplasm of liver
brain metastases
metastasis
serum bilirubin level
osimertinib
  • 2 views
  • 25 Jan, 2021
  • 1 location
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases

20-40% of patients with NSCLC will develop brain metastases at some point during their course of disease. Osimertinib has demonstrated intracranial activity in EFGR mutated NSCLC with

  • 50 views
  • 25 Jan, 2021
  • 13 locations
Whole Genomic Landscape of Advanced EGFR-mutant NSCLC

-nave NSCLC patients with EGFR-activating mutations who receive a first-line osimertinib orally at a dose of 80mg once daily.

  • 3 views
  • 25 Jan, 2021
  • 1 location
A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer

treatment are allowed, except for other epidermal growth factor receptor inhibitors [EGFRis]) for Phase 1; and for Phase 2, subjects who have T790M+ and are osimertinib nave (Cohort 1), and also those who

epidermal growth factor receptor
egfr t790m
measurable disease
kinase inhibitor
EGFR
  • 51 views
  • 15 Jul, 2020
  • 8 locations
Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

strategy for delivering osimertinib (upfront versus sequential treatment after 1st generation EGFR TKI) in EGFR mutant NSCLC patients. Finally, the trial will also explore the mechanisms of acquired

secondary malignant neoplasm of liver
egfr t790m
lung adenocarcinoma
neutrophil count
platelet count
  • 80 views
  • 23 Jan, 2021
  • 22 locations
A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed Mesenchymal-epithelial Transition Factor (MET) Amplified Non-small Cell Lung Cancer (NSCLC) (INSIGHT 2)

This study will assess the antitumor activity, safety, tolerability, and pharmacokinetics (PK) of the MET inhibitor tepotinib combined with the 3rd generation EGFR inhibitor osimertinib in

epidermal growth factor receptor
lung carcinoma
stage iv non-small cell lung cancer
growth factor
osimertinib
  • 84 views
  • 22 Dec, 2020
  • 102 locations